Therapy News and Research

RSS

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Adempas (riociguat) is available in the UK today as the first drug treatment for CTEPH, to treat adult patients with WHO Functional Class (FC) II to III with inoperable or persistent disease to improve exercise capacity.

1 Apr 2014

Scientists develop new substance that could simplify manufacture of cell therapy

Scientists at The University of Nottingham have developed a new substance which could simplify the manufacture of cell therapy in the pioneering world of regenerative medicine.

1 Apr 2014

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Men with prostate cancer face tough choices: when, or even if, to treat their cancer; what procedure to use; and how to balance their chosen treatment with their quality of life. Now, a new multicenter clinical trial seeks to offer men another option - one that physicians hope will treat prostate cancers with fewer side effects.

1 Apr 2014

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Patients with an autoimmune disease have a 3.8-fold increased risk of developing epilepsy, according to a new population-level study from Boston Children's Hospital based on health insurance claim data.

1 Apr 2014

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Gastric bypass and sleeve gastrectomy - two of the most commonly used bariatric surgeries - are more effective than intensive medical therapy alone when it comes to managing uncontrolled type 2 diabetes in overweight or obese patients after three years, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick.

31 Mar 2014

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).

31 Mar 2014

ZO Skin Health, Cellogique announce launch of ZO Medical products in Middle East

ZO Skin Health, Inc. and Cellogique Corporation are pleased to announce the launch of the ZO Medical product line to the Middle East region at The Dubai World Dermatology & Laser Conference & Exhibition – Dubai Derma, April 8-10, 2014.

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed.

From Clinigen Group 31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

Researchers quantify proportion of adults potentially affected by updated 2014 BP recommendations

Applying the updated 2014 blood pressure (BP) guideline to the U.S. population suggests that nearly 6 million adults are no longer classified as needing hypertension medication, and that an estimated 13.5 million adults would now be considered as having achieved goal blood pressure, primarily older adults, according to a JAMA study released online to coincide with the 2014 American College of Cardiology Scientific Sessions.

31 Mar 2014

MADIT-CRT study: Boston Scientific CRT defibrillator reduces risk of death in mild heart failure patients

In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's exclusively sponsored and landmark Multicenter Automatic Defibrillator Implantation Trial – Cardiac Resynchronization Therapy (MADIT-CRT) study demonstrated significant and sustained survival benefit for the indicated population.

31 Mar 2014

Study on effects of cholesterol-lowering medications on sexual health

A new study is giving hope to older men who are concerned about the effects of cholesterol-lowering medications on their sexual health.

31 Mar 2014

Therapy News and Research

Bayer’s Adempas now available in the UK to treat patients with CTEPH

Scientists develop new substance that could simplify manufacture of cell therapy

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Bariatric surgery more effective than intensive medical therapy for managing type 2 diabetes

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

New study shows anti-anxiety drugs and sleeping pills associated with increased risk of death

FDA grants orphan drug designation for Kite Pharma's cancer immunotherapy product

ZO Skin Health, Cellogique announce launch of ZO Medical products in Middle East

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

Researchers quantify proportion of adults potentially affected by updated 2014 BP recommendations

MADIT-CRT study: Boston Scientific CRT defibrillator reduces risk of death in mild heart failure patients

Study on effects of cholesterol-lowering medications on sexual health

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News